NGFA: President's FY 2023 Budget Increases Funding For Food and Feed Activities

By David Fairfield, Senior Vice President, Feed

The U.S. Food and Drug Administration (FDA) announced on March 28 it is requesting a total budget of $8.4 billion as part of the president’s fiscal year (FY) 2023 budget (Oct. 1, 2022 to Sept. 30, 2023) — a nearly 34% ($2.1 billion) increase over the agency’s FY 2022 appropriated funding level for investments in public health modernization, food and feed safety, medical product safety programs, and other public health infrastructure.

FDA’s request included the following increases related to food and feed:

$43 million in additional investments in food safety modernization, including animal food safety oversight. The increase is intended to support the agency’s continued implementation of the New Era of Smarter Food Safety and other core food safety efforts to enable FDA to strengthen data-driven approaches to protecting consumers, allocating regulatory oversight resources based on risk and improving FDA’s capacity to quickly respond to ongoing and evolving public health challenges.

The budget request also advances mutual reliance efforts by providing significant funding to state animal food programs.

In partnership with states, FDA intends to expand efforts to modernize, harmonize, and transform the U.S. animal food inspection system to become more comprehensive and prevention oriented.

$24 million to optimize inspections and enhance inspectional capacity.

The budget request increases support for the recruitment and training of new FDA investigators to improve the efficiency of the agency’s human and animal food and medical product inspectional operations.

$5 million in additional funding to boost review capacity for premarket animal drug submissions.

In requesting the increase, FDA said continuing to meet performance commitments, including reduced application review times for animal drug reviews, is a priority for the agency.

The number of animal drug submissions received have steadily increased over time and FDA says more resources are needed to review the additional submissions within agreed upon user fee timeframes and subsequently increasing the availability of safe and effective animal drug products.

The President’s FY 2023 budget serves as a starting point for future discussions within Congress to approve actual FY 2023 budget appropriations.